David B. Agus

16.1k total citations · 2 hit papers
116 papers, 8.0k citations indexed

About

David B. Agus is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, David B. Agus has authored 116 papers receiving a total of 8.0k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Pulmonary and Respiratory Medicine, 41 papers in Molecular Biology and 40 papers in Oncology. Recurrent topics in David B. Agus's work include Prostate Cancer Treatment and Research (52 papers), HER2/EGFR in Cancer Research (15 papers) and Radiopharmaceutical Chemistry and Applications (14 papers). David B. Agus is often cited by papers focused on Prostate Cancer Treatment and Research (52 papers), HER2/EGFR in Cancer Research (15 papers) and Radiopharmaceutical Chemistry and Applications (14 papers). David B. Agus collaborates with scholars based in United States, United Kingdom and Japan. David B. Agus's co-authors include Parag Mallick, Darren Kessner, Robert Burke, Matt Chambers, Howard I. Scher, Carlos Cordon‐Cardo, Brian Higgins, Mitchell E. Gross, David W. Golde and Marija Drobnjak and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

David B. Agus

115 papers receiving 7.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

ProteoWizard: open source software for rapid proteomics tools development

2008 1.5k citations David B. Agus, Parag Mallick et al. profile →
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.

2000 521 citations David B. Agus, Howard I. Scher et al. PubMed profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David B. Agus United States	47	3.9k	2.2k	1.9k	1.0k	1.0k	116	8.0k
Florence I. Raynaud United Kingdom	55	5.5k 1.4×	2.6k 1.2×	2.1k 1.1×	719 0.7×	1.2k 1.2×	242	10.2k
Natalie J. Serkova United States	49	3.5k 0.9×	1.0k 0.5×	1.0k 0.5×	536 0.5×	1.2k 1.1×	171	7.7k
Dean A. Troyer United States	48	3.1k 0.8×	1.3k 0.6×	3.6k 1.8×	341 0.3×	1.3k 1.2×	150	8.0k
Pierre P. Massion United States	54	5.1k 1.3×	3.1k 1.5×	3.8k 2.0×	1.2k 1.1×	2.1k 2.1×	225	10.4k
Donna M. Peehl United States	61	5.6k 1.4×	2.3k 1.1×	3.5k 1.8×	613 0.6×	2.2k 2.1×	211	11.8k
James D. Brooks United States	60	6.9k 1.8×	1.7k 0.8×	6.1k 3.1×	925 0.9×	2.7k 2.6×	365	14.2k
Dan Theodorescu United States	69	7.5k 1.9×	3.6k 1.7×	3.1k 1.6×	434 0.4×	2.8k 2.7×	335	14.6k
Hideo Suzuki Japan	50	6.3k 1.6×	2.5k 1.2×	753 0.4×	492 0.5×	1.7k 1.7×	496	11.2k
Yasuhiro Fujiwara Japan	59	4.8k 1.2×	6.5k 3.0×	2.5k 1.3×	1.4k 1.4×	2.2k 2.1×	551	13.5k
Matthew M. Ames United States	51	4.0k 1.0×	2.7k 1.2×	923 0.5×	239 0.2×	1.1k 1.1×	239	9.3k

Countries citing papers authored by David B. Agus

Since Specialization

Citations

This map shows the geographic impact of David B. Agus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David B. Agus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David B. Agus more than expected).

Fields of papers citing papers by David B. Agus

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David B. Agus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David B. Agus. The network helps show where David B. Agus may publish in the future.

Co-authorship network of co-authors of David B. Agus

This figure shows the co-authorship network connecting the top 25 collaborators of David B. Agus. A scholar is included among the top collaborators of David B. Agus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David B. Agus. David B. Agus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Barker, Anna D., et al.. (2023). An Inflection Point in Cancer Protein Biomarkers: What was and What's Next. Molecular & Cellular Proteomics. 22(7). 100569–100569. 14 indexed citations

Liu, Chao, Grzegorz Zapotoczny, Nolan Ung, et al.. (2021). Paradoxical androgen receptor regulation by small molecule enantiomers. Proceedings of the National Academy of Sciences. 118(12). 3 indexed citations

Sha, Fei, et al.. (2020). Deep learned tissue “fingerprints” classify breast cancers by ER/PR/Her2 status from H&E images. Scientific Reports. 10(1). 7275–7275. 63 indexed citations

Gross, Mitchell E., David B. Agus, Tanya B. Dorff, et al.. (2020). Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer. Prostate Cancer and Prostatic Diseases. 24(1). 61–68. 42 indexed citations

Kani, Kian, Carolina Garri, Katrin Tiemann, et al.. (2017). JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines. Molecular Cancer Therapeutics. 16(8). 1645–1657. 18 indexed citations

Lam, Larry, Liudmilla Rubbi, Roberto Ferrari, et al.. (2016). Epigenetic changes mediated by polycomb repressive complex 2 and E2a are associated with drug resistance in a mouse model of lymphoma. Genome Medicine. 8(1). 54–54. 10 indexed citations

Chiang, Chun-Te, et al.. (2016). A high-content image-based method for quantitatively studying context-dependent cell population dynamics. Scientific Reports. 6(1). 29752–29752. 49 indexed citations

Mumenthaler, Shannon M., Jasmine Foo, Kevin Leder, et al.. (2015). The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells. SHILAP Revista de lepidopterología. 7 indexed citations

Dzau, Victor J., Geoffrey S. Ginsburg, Karen Van Nuys, David B. Agus, & Dana P. Goldman. (2015). Aligning incentives to fulfil the promise of personalised medicine. The Lancet. 385(9982). 2118–2119. 59 indexed citations

10.

Dreicer, Robert, David B. MacLean, Ajit Suri, et al.. (2014). Phase I/II Trial of Orteronel (TAK-700)—an Investigational 17,20-Lyase Inhibitor—in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 20(5). 1335–1344. 34 indexed citations

11.

Kani, Kian, Vítor M. Faça, Lindsey D. Hughes, et al.. (2012). Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition. Molecular Cancer Therapeutics. 11(5). 1071–1081. 6 indexed citations

12.

Jain, Anjali, Elicia Penuel, Sheldon Mink, et al.. (2010). HER Kinase Axis Receptor Dimer Partner Switching Occurs in Response to EGFR Tyrosine Kinase Inhibition despite Failure to Block Cellular Proliferation. Cancer Research. 70(5). 1989–1999. 56 indexed citations

13.

Mink, Sheldon, et al.. (2010). Cancer-Associated Fibroblasts Derived from EGFR-TKI–Resistant Tumors Reverse EGFR Pathway Inhibition by EGFR-TKIs. Molecular Cancer Research. 8(6). 809–820. 72 indexed citations

14.

Bearer, Elaine L., John Lowengrub, Hermann B. Frieboes, et al.. (2009). Multiparameter Computational Modeling of Tumor Invasion. Cancer Research. 69(10). 4493–4501. 98 indexed citations

15.

Meyerowitz, Beth E., et al.. (2008). Predictors of affect following treatment decision‐making for prostate cancer: conversations, cognitive processing, and coping. Psycho-Oncology. 18(5). 508–514. 39 indexed citations

16.

Takai, Noriyuki, Anjali Jain, Norihiko Kawamata, et al.. (2005). 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth. Cancer. 104(12). 2701–2708. 62 indexed citations

17.

Osman, Islam, Howard I. Scher, Marija Drobnjak, et al.. (2001). HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer.. PubMed. 7(9). 2643–7. 130 indexed citations

18.

Agus, David B., Robert W. Akita, William D. Fox, et al.. (2000). A potential role for activated HER-2 in prostate cancer.. PubMed. 27(6 Suppl 11). 76–83; discussion 92. 36 indexed citations

19.

Agus, David B., Howard I. Scher, Brian Higgins, et al.. (1999). Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models.. PubMed. 59(19). 4761–4. 123 indexed citations

20.

Agus, David B., David W. Golde, George Sgouros, et al.. (1998). Positron emission tomography of a human prostate cancer xenograft: association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal.. PubMed. 58(14). 3009–14. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact